Performance of estimation methods in modelling the kinetics of respiratory virus infection

Background: Viral kinetic (VK) models are progressively being used to support the dose justification of drugs used to treat influenza and Respiratory Syncytial Virus infection 1-2. However, study design considerations and data limitations often present challenges when developing models that describe the VK following placebo and drug treatment. We explore the performance of estimation methods […]

Population modelling of influenza viral kinetics, immune response, symptom dynamics and the effect of oseltamivir

Background: Oseltamivir is an oral prodrug indicated for the treatment and prophylaxis of influenza. However, there is a paucity of disease models that incorporate the time course of influenza infection with antiviral effects and host system dynamics. This information is critical to optimise dose selection and duration of treatment. Objectives: To develop an influenza disease […]

Oseltamivir dosing optimisation in patients treated with automated peritoneal dialysis

Background: Peritoneal Dialysis (PD) is a renal replacement therapy commonly used in patients with end-stage renal disease (ESRD). Automated PD (APD) is more convenient than traditional continuous ambulatory PD (CAPD) because the manual delivery and drainage of dialysate is not required. Oseltamivir is an oral prodrug widely indicated for the treatment of influenza infections. The […]

Mechanism-based population modelling of dihydoartemisinin pharmacodynamics in murine malaria

Background: Murine models are powerful tools for studying erythrocytic stages of malaria infection, because parasite morphology and development are similar to that in human malaria. However, mechanism-based pharmacodynamic (PD) models for antimalarials are generally lacking, and are required to optimise dosing. Objectives: To describe the growth cycle for Plasmodium berghei and the parasitocidal effect of […]

Development of fluconazole dosage guidelines in critically ill patients receiving continuous venovenous hemodiafiltration

Objectives: To investigate the pharmacokinetics of fluconazole in critically ill anuric patients receiving continuous venovenous hemodiafiltration (CVVHDF), and to determine a dosing regimen that achieves appropriate pharmacodynamic endpoints in this population. Design: An open-labeled study performed over a 28 month period. Setting: Intensive care unit at the Royal Brisbane and Womens’ Hospital in Australia. Patients: […]